India Made AstraZeneca’s COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution: Reuters
Serum Institute of India’s (SII) CEO Adar Poonawalla said he was trying to resolve EU travel problems facing Indians inoculated…
Biogen’s Costly Alzheimer’s Treatment May Face Restricted Medicare Access: WSJ
The recent approval of Biogen Inc’s (NASDAQ:BIIB) high-price Alzheimer’s drug is raising questions about who will have access to the $56,000/year treatment…
UK Study Of COVID-19 Shots Mix-Match Shows Immune Response, Can Add Flexibility To Vaccination Programs: CNBC
Mixing and matching the coronavirus vaccines made by Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and AstraZeneca Plc (NASDAQ:AZN) – Oxford showed a “robust”…
Acutus Medical National Institutes Of Health ClinicalTrials.gov Study Record Detail For Co.’s ‘AcQBlate Force Sensing Ablation System Study for Atrial Fibrillation (AcQForce AF-EU)’
https://clinicaltrials.gov/ct2/show/NCT04941391
UPDATE: CEL-SCI Earlier Release Showed Co. When Its Multikine Treatment Was Administered And Higher Risk Was Compared To Control, Study Did Not Achieve Its Primary Endpoint
When the complete study population to which the Multikine treatment regimen was administered (i.e., the combined lower risk (no chemotherapy) and higher risk (with chemotherapy added)) was compared to control, the study
Tandem Diabetes Sunday Highlighted Presentations Showing Improvements With Control-IQ Technology
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of the t:slim X2™ insulin pump with Control-IQ®
Eli Lilly Late Saturday Highlighted SURPASS-1 Results Were Published In ‘The Lancet,’ Showed Tirzepatide’s Superior A1C Blood Type, body Weight Reductions vs Placebo
Data presented at ADA's 81st Scientific Sessions® show the highest dose of tirzepatide (15 mg) reduced A1C by 2.07 percent and weight by 9.5 kg (20.9 lb., 11.0 percent)
Majority of study population was
Insulet Late Saturday Reported Co.’s Omnipod 5 Automated Insulin Delivery System Pivotal Studies Showed Improved Outcomes Across Lifespan From Ages 2-70 Years
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced promising results from its latest pivotal trial
Sana Biotech Early Saturday Highlighted Presentation Of Data Showing Survival Of Transplanted Hypoimmune Stem Cells Without Immunosuppression In Non-Human Primates
First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression
Transplanting allogeneic cells into a primate without immune
Arrowhead Pharma Early Saturday Highlighted Presentation Of Added Interim 48-Week Liver Biopsy Results From Ongoing Study For Its Investigational RNA Interference Therapeutic Being Co-Developed With Takeda
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the